rexahn pharmaceuticals inc (RNN) Key Developments
Rexahn Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter of 2015
Aug 10 15
Rexahn Pharmaceuticals, Inc. reported earnings results for the second quarter of 2015. For the period, the company reported net loss was $3.2 million, or $0.02 per share, compared to a net income of $0.2 million, or a breakeven on a per share basis in second quarter of 2014.
Rakesh Soni to Resign as President and Chief Operating Officer of Rexahn Pharmaceuticals, Inc., Effective July 21, 2015
Jul 17 15
On July 13, 2015, Rexahn Pharmaceuticals, Inc. was notified by Rakesh Soni, the company's President and Chief Operating Officer, that Mr. Soni will resign his employment with the company effective on July 21, 2015.
Rexahn Pharmaceuticals, Inc. Awards Patent in Japan for Novel Targeted Cancer Drug Delivery Platform
Jul 14 15
Rexahn Pharmaceuticals, Inc. announced that it was entitled Polymeric Systems for the Delivery of Anticancer Drugs for the Company's novel CPMA drug delivery platform. This new CPMA drug delivery platform technology, developed by Rexahn, enables more precise, targeted delivery of anti-cancer drugs directly into cancer cells. There is a significant unmet need in the oncology field for drugs which selectively target and kill cancer cells while sparing normal, healthy cells. By utilizing proprietary CPMA polymer drug delivery technology and combining it with currently approved anti-cancer drugs, hope to transport anti-cancer drugs directly into cancerous cells where their cytotoxic activity can be most effective, thereby increasing efficacy and minimizing the harmful side effects associated with traditional cancer therapy.
Rexahn Pharmaceuticals, Inc. Appoints Peter Brandt as Chairman of the Board
Jun 22 15
Rexahn Pharmaceuticals, Inc. announced the appointment of Peter Brandt as Chairman of the Board. Dr. Chang Ahn, Rexahn’s founder, will remain on the Board as Chairman Emeritus and will continue in his role as the company’s Chief Scientist. A Director of Rexahn since 2010, Mr.Brandt previously served as President and Chief Executive Officer of Noven Pharmaceuticals until its acquisition by Hisamitsu Pharmaceutical in 2009.
National Cancer Institute Selects RX-21101 of Rexahn Pharmaceuticals, Inc for its Preclinical Characterization Program
Jun 8 15
Rexahn Pharmaceuticals, Inc. announced that its drug candidate RX-21101 was selected by the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL) for its preclinical characterization program to help facilitate the advance of RX-21101 towards human clinical trials. RX-21101 is a polymer conjugated form of docetaxel that contains a signaling moiety which directs the drug into the tumor. This approach may maximize the level of docetaxel in the tumor and may minimize the level of freely circulating docetaxel in the body, which may result in increased anti-tumor activity and a reduction of adverse events. NCL will conduct an extensive series of preclinical studies on RX-21101 including physiochemical characterization, in-vitro cytotoxicity/hematology/immunology studies, and in vivo rodent pharmacokinetic studies. These studies, together with the additional work being performed by Rexahn scientists, will provide the foundation for filing an investigational new drug (IND) application to start Phase I clinical testing.